Informações do curso
Conferences and Meetings
Oral Abstracts
Oral Abstracts
Categoria: Conferences and Meetings
Nome curto: 2023 AM Invited Program + Oral Abstracts-Oral Abstracts
Data de início do curso: 12/15/2023
Seções
Em geral
0 activities
Oral Abstracts
0 activities
101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation
7 activities
101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease
6 activities
102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis
7 activities
112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia
6 activities
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease
7 activities
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans
7 activities
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation
6 activities
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease
7 activities
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future
7 activities
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors
7 activities
201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes
7 activities
201. Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias
5 activities
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity
7 activities
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis
7 activities
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis
7 activities
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias
5 activities
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes
7 activities
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia
6 activities
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations
7 activities
321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies
7 activities
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care
6 activities
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan
5 activities
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders
7 activities
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations
7 activities
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care
6 activities
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism
7 activities
401. Blood Transfusion: Advances in Transfusion Medicine
6 activities
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness
7 activities
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress
7 activities
503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries
5 activities
503. Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations
6 activities
506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease
7 activities
508. Bone Marrow Failure: Acquired: Immune AA and VEXAS – Biology, Diagnosis and Treatment
7 activities
508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials
6 activities
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc.
7 activities
602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells
7 activities
602. Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy
6 activities
602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics
7 activities
602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms
6 activities
603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis
6 activities
603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression
6 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies
7 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies
6 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies
7 activities
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma
6 activities
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias
7 activities
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL
6 activities
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML – De Novo and Myelodysplasia-Related
7 activities
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML– Molecular Targets, Ethnicity, and AI
7 activities
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication
7 activities
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches
6 activities
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL
7 activities
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL
7 activities
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML
7 activities
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL
7 activities
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML
7 activities
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents
7 activities
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML
6 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics
6 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features
7 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control
5 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response
7 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant
7 activities
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response
5 activities
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis
6 activities
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment
7 activities
621. Lymphomas: Translational – Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics
7 activities
621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc.
6 activities
621. Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma
6 activities
622. Lymphomas: Translational – Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma
6 activities
622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma
5 activities
623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents
5 activities
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy
7 activities
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL
7 activities
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy
7 activities
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas
6 activities
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma
5 activities
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas
7 activities
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas
6 activities
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma
6 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas
6 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas
6 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents
7 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL
6 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient
4 activities
627. Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL
7 activities
631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models
7 activities
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery
7 activities
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context
7 activities
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches
7 activities
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication
7 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies
6 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers
7 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies
7 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs
6 activities
636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications
7 activities
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Genomic Classification and Prognostication of MDS
7 activities
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS
7 activities
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS
6 activities
641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation
6 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation
6 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia
6 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs
6 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States
6 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions
5 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment
6 activities
652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma
6 activities
652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics
7 activities
652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes
7 activities
652. Multiple Myeloma: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance - Novel Insights on the Relevance of Gammopathies and Misc.
7 activities
652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma
5 activities
652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma
6 activities
652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications
7 activities
653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma
7 activities
653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma
6 activities
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis
6 activities
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders
5 activities
701. Experimental Transplantation: Basic and Translational: GVHD, Intestinal Immunity, and the Gut Microbiome
7 activities
701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution
7 activities
703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights
7 activities
703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies
4 activities
703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies
4 activities
703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers
7 activities
703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies
6 activities
703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights
7 activities
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas
5 activities
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies
7 activities
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies
6 activities
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
7 activities
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
7 activities
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence
6 activities
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity
7 activities
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors
7 activities
711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool
6 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Improving Outcomes by Reducing Transplant-Related Complications
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia
6 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management
6 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology
6 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment
7 activities
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes
7 activities
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship From Clinical Trials And Observations
7 activities
731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach
6 activities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection
6 activities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation
7 activities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification
5 activities
801. Gene Therapies: New Approaches From Bench to Bedside
7 activities
801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders
6 activities
802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders
6 activities
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology
5 activities
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology
7 activities
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology
6 activities
901. Health Services and Quality Improvement – Non-Malignant Conditions: Access to Quality Care in Classical Hematology
7 activities
901. Health Services and Quality Improvement – Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education
5 activities
901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders
7 activities
901. Health Services and Quality Improvement – Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum
7 activities
902. Health Services and Quality Improvement – Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias
7 activities
902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy
7 activities
902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data
5 activities
903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies
7 activities
903: Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies
6 activities
904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients
7 activities
904. Outcomes Research – Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease
7 activities
904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders
7 activities
905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma
7 activities
905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology
7 activities
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data
7 activities
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Myeloma: What's New?
7 activities
905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies
7 activities
905. Outcomes Research – Lymphoid Malignancies: Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma
7 activities
906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes
7 activities
906. Outcomes Research – Myeloid Malignancies: Risk Factors and Health Disparities
7 activities
906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies
6 activities
177
963